Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in Systemic Lupus Erythematosus
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objective
We aim to explore the role of mechanistic target of rapamycin complex (mTORC) 2 in systemic lupus erythematosus (SLE) development, the in vivo regulation of mTORC2 by type I interferon (IFN) signaling in autoimmunity, and to use mTORC2 targeting therapy to ameliorate lupus-like symptoms in an in vivo lupus mouse model and an in vitro coculture model using human PBMCs.
Method
We first induced lupus-like disease in T cell specific Rictor , a key component of mTORC2, deficient mice by topical application of imiquimod (IMQ) and monitored disease development. Next, we investigated the changes of mTORC2 signaling and immunological phenotypes in type I IFNAR deficient Lpr mice. We then tested the beneficial effects of anti- Rictor antisense oligonucleotide ( Rictor -ASO) in a mouse model of lupus: MRL/ lpr mice. Finally, we examined the beneficial effects of RICTOR -ASO on SLE patients’ PBMCs using an in vitro T-B cell coculture assay.
Results
T cell specific Rictor deficient mice have reduced age-associated B cells, plasma cells and germinal center B cells, and less autoantibody production than WT mice following IMQ treatment. IFNAR1 deficient Lpr mice have reduced mTORC2 activity in CD4 + T cells accompanied by restored CD4 + T cell glucose metabolism, partially recovered T cell trafficking, and reduced systemic inflammation. In vivo Rictor -ASO treatment improves renal function and pathology in MRL/ lpr mice, along with improved immunopathology. In human SLE (N = 5) PBMCs derived T-B coculture assay, RICTOR- ASO significantly reduce immunoglobulin and autoantibodies production (P < 0.05).
Conclusion
Targeting mTORC2 could be a promising therapeutic for SLE.
